Blood-pressure & pain-signaling peptide from hemoglobin (LVV-hemorphin-7)
A natural peptide released from red blood cell protein that activates the brain's opioid system and helps lower blood pressure; found in human spinal fluid; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
LVV-hemorphin-7 is a 10-amino acid opioid peptide derived by proteolytic cleavage from the β-chain of hemoglobin (gene HBB). It belongs to the hemorphin family — a class of peptides released from the same β-globin region by endogenous proteases or by pepsin-mediated hydrolysis during digestion. The "LVV" prefix designates the three N-terminal residues (Leu-Val-Val) that extend the 7-residue hemorphin-7 core (YPWTQRF); the "7" refers to the 7-residue opioid-active sequence itself. LVV-hemorphin-7 displays μ-opioid receptor binding activity and inhibits angiotensin-converting enzyme (ACE), linking it to both opioid signaling and cardiovascular regulation. The stored sequence LVVYPWTQRF represents the full 10-residue peptide as found in human cerebrospinal fluid (Silberring and Nyberg 1997); shorter family members — hemorphin-7 (YPWTQRF, 7 aa), VV-hemorphin-7 (9 aa), and others — all share the YPWT opioid-active core.
Hemorphins are unusual among endogenous opioid peptides because they derive from hemoglobin, a structural oxygen-carrying protein not previously considered a prohormone. They are generated under conditions including proteolytic tissue catabolism, blood digestion in the gastrointestinal tract, and potentially by tissue-specific proteases in the brain and spinal cord. No hemorphin-family peptide has an approved clinical use; all characterization is from in vitro and animal models.
History
The hemorphin family was discovered by Brantl, Gramsch, Lottspeich, and Mertz in 1986 at the Max Planck Institute for Psychiatry (Munich). Working with bovine hemoglobin, Brantl and colleagues identified short opioid-active peptide sequences released by proteolysis of bovine β-hemoglobin and named them "hemorphins" to reflect their hemoglobin origin and morphine-like opioid activity (Brantl et al. 1986). The 1986 European Journal of Pharmacology report showed that hemorphin-derived peptides were active in the guinea-pig ileum assay — a classic opioid bioassay — and demonstrated opioid receptor binding affinity comparable to enkephalins. This established hemoglobin as an unexpected prohormone source for endogenous opioid ligands.
Subsequent work through the 1990s characterized the extended LVV forms specifically. Garreau and colleagues (1995) demonstrated that both VV-hemorphin-7 and LVV-hemorphin-7 were released from human hemoglobin by in vitro pepsin hydrolysis and showed morphine-like opioid receptor binding activity, establishing that the LVV extension did not abolish the opioid activity of the hemorphin-7 core. The same period saw characterization of ACE-inhibitory activity by hemorphins.
The endogenous occurrence of LVV-hemorphin-7 in human cerebrospinal fluid was documented by Silberring and Nyberg (1997), confirming that hemorphin peptides are generated in vivo in the central nervous system and not only during gastrointestinal digestion. This finding raised the possibility of CNS-relevant opioid activity beyond dietary peptide effects.
What it does
μ-Opioid receptor binding: LVV-hemorphin-7 and its shorter relatives bind opioid receptors, with the YPWT core sequence providing the primary pharmacophore. Hemorphin binding at μ-opioid receptors was demonstrated in radioligand competition assays using [³H]naloxone and [³H]DAGO (Garreau et al. 1995). The affinity at μ-receptors is lower than for synthetic opioid agonists or for endogenous peptides like β-endorphin, but is sufficient for detectable opioid receptor occupancy in assay systems. The LVV extension may modulate receptor selectivity or potency relative to the bare hemorphin-7 sequence; the opioid structure–activity relationship of the LVV prefix is not fully characterized.
ACE inhibition: Hemorphins including LVV-hemorphin-7 inhibit angiotensin-converting enzyme (ACE) — the enzyme that converts angiotensin I to angiotensin II (vasoconstrictor) and degrades bradykinin (vasodilator). This dual ACE-inhibitory and opioid activity suggests that LVV-hemorphin-7, if generated endogenously at sufficient concentrations, could contribute to both analgesic and antihypertensive effects simultaneously. The ACE-inhibitory potency of hemorphin peptides is in the micromolar range — lower than clinically used ACE inhibitors, but relevant for local tissue concentrations.
Endogenous occurrence in cerebrospinal fluid: LVV-hemorphin-7 has been detected in human CSF (Silberring and Nyberg 1997), establishing that the peptide is generated endogenously in the central nervous system and not only as a result of peripheral hemoglobin proteolysis or dietary protein digestion. The source of LVV-hemorphin-7 in CSF — whether from local CNS hemoglobin processing, blood-CSF barrier transit, or other proteolytic release — is not definitively established. Its endogenous CNS presence is consistent with a physiological opioid signaling role, but pharmacodynamic significance at measured CSF concentrations is uncertain.
Peptic generation from dietary hemoglobin: During gastric digestion, pepsin cleaves dietary hemoglobin from red meat to release hemorphin-family peptides. VV-hemorphin-7 and LVV-hemorphin-7 are both released during in vitro peptic hydrolysis of human hemoglobin (Garreau et al. 1995), suggesting that dietary hemoglobin consumption generates these opioid-active ACE-inhibitory peptides. Whether dietary hemorphin absorption into systemic circulation occurs at concentrations sufficient for physiological effects is not established.
Evidence
- Human: No clinical trials have been conducted with LVV-hemorphin-7 or any hemorphin-family peptide. ClinicalTrials.gov returns 0 results for "hemorphin" or "LVV-hemorphin" as of 2026. The endogenous presence of LVV-hemorphin-7 in human cerebrospinal fluid has been documented analytically (Silberring and Nyberg 1997).
- Animal: Hemorphins were originally characterized from bovine hemoglobin digests and shown to be active in guinea-pig ileum bioassay — a standard opioid bioassay (Brantl et al. 1986).
- In vitro: LVV-hemorphin-7 exhibits μ-opioid receptor binding and ACE-inhibitory activity in cell-free and radioligand assay systems. Garreau and colleagues (1995) showed that peptic hydrolysis of human hemoglobin releases LVV-hemorphin-7 and confirmed opioid receptor binding activity by radioligand competition.
Myths and misconceptions
- "Hemorphins are dietary opioids that cause addiction through food consumption." While hemorphins can be generated by peptic digestion of dietary hemoglobin in red meat, the systemic bioavailability of intact LVV-hemorphin-7 after oral ingestion is not established. Most peptides are further degraded in the intestinal lumen and by intestinal and hepatic peptidases before reaching systemic circulation intact. The documented endogenous CNS presence most likely reflects local CNS generation rather than dietary absorption. No evidence supports a role for dietary hemorphin in opioid dependence or addiction.
- "LVV-hemorphin-7 is the same as enkephalin or endorphin because it binds opioid receptors." Enkephalins (Met-enkephalin: YGGFM, Leu-enkephalin: YGGFL) and β-endorphin are derived from PENK and POMC — dedicated prohormones evolved for opioid signaling. LVV-hemorphin-7 is derived from hemoglobin, an oxygen-transport protein whose primary role is entirely unrelated to nociception. Hemorphins are also structurally distinct from enkephalins — the YPWT core bears no sequence homology to the YGG opioid core of enkephalins.
- "Hemorphin ACE inhibition makes it equivalent to clinical ACE inhibitors for hypertension treatment." Clinical ACE inhibitors (captopril, lisinopril, ramipril) are specifically designed, metabolically stable inhibitors with inhibitory potency in the nanomolar range. Hemorphins inhibit ACE with potency in the micromolar range under in vitro conditions; whether endogenous concentrations in vivo reach ACE-inhibitory levels is not established. No clinical trial has evaluated LVV-hemorphin-7 or related hemorphins as antihypertensive therapeutics.
Common questions
Q: Why does hemoglobin contain opioid-active sequences if its function is oxygen transport? A: The presence of cryptic opioid sequences within hemoglobin does not imply that opioid signaling is hemoglobin's function. The YPWT core sequence has an intrinsic affinity for opioid receptor binding pockets that is independent of the evolutionary pressure that shaped the globin fold for oxygen transport. Many structural proteins contain short sequences that are coincidentally active at receptors when liberated by proteolysis. Whether hemorphin generation serves any physiological regulatory purpose — or is simply a consequence of inevitable hemoglobin turnover — remains unresolved. The detection of LVV-hemorphin-7 in CSF is consistent with a physiological role, but whether it represents a dedicated signaling pathway or background proteolytic noise has not been definitively determined.
Q: How does LVV-hemorphin-7 relate to other food-derived opioid peptides like casomorphins? A: Both hemorphins and casomorphins are "exorphins" — opioid-active peptides released from food proteins by peptic or intestinal proteolysis. β-Casomorphins (from milk casein) and hemorphins (from meat hemoglobin) share the general concept of opioid sequences cryptically present within non-opioid food proteins, revealed by digestion. They differ in precursor protein, amino acid sequence, and opioid receptor selectivity profile. β-Casomorphin-7 has been studied in the context of infant nutrition and autism hypotheses (though causality is disputed); hemorphins have been studied primarily in the context of endogenous CNS opioids and ACE inhibition.
Related peptides
- Vasostatin-1 — Vasostatin-1: another endogenous peptide derived from a precursor protein not primarily categorized as a prohormone (chromogranin A, CHGA); vasostatin-1 and LVV-hemorphin-7 both illustrate the "structural protein as cryptic peptide source" pattern
- Pancreastatin — Pancreastatin: a CHGA-derived peptide from the same precursor as vasostatin-1, demonstrating that multiple distinct bioactive peptides can arise from a single non-dedicated precursor — analogous to the multiple hemorphin variants from the hemoglobin beta chain
- Corticotropin — ACTH / Corticotropin: an established example of proteolytic prohormone processing (POMC → ACTH, β-endorphin, and other fragments), contrasting with hemorphin release from a structural protein not evolved as a prohormone
▸3-letter notation
▸citationbibtex
@peptide{pep04489,
sequence = {LVVYPWTQRF},
target = {},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}